Skip to content
<title>Channels - Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025 :: FRELIP Discovery
Channels Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026
Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - California, October 2025-January 2026
Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025
Interim Effectiveness Estimates of 2025 Southern Hemisphere Influenza Vaccines in Preventing Influenza-Associated Outpatient and Hospitalized Illness - Eight Southern Hemisphere Countries, March-September 2025
Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025
Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products - United States, October 2024-February 2025
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025-26 Influenza Season
Influenza Vaccination Coverage Among Nursing Home Residents and Health Care Personnel - United States, 2024-25 Influenza Season
Human-to-Human Rabies Transmission via Solid Organ Transplantation from a Donor with Undiagnosed Rabies - United States, October 2024-February 2025
Clade Ib Mpox Outbreak - Kenya, July 2024-February 2025
Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel - United States, 2024-25 Respiratory Virus Season
Influenza-Associated Pediatric Deaths - United States, 2024-25 Influenza Season
Pediatric Influenza-Associated Encephalopathy and Acute Necrotizing Encephalopathy - United States, 2024-25 Influenza Season
Influenza-Associated Hospitalizations During a High Severity Season - Influenza Hospitalization Surveillance Network, United States, 2024-25 Influenza Season
Respiratory Syncytial Virus Immunization Coverage Among Infants Through Receipt of Nirsevimab Monoclonal Antibody or Maternal Vaccination - United States, October 2023-March 2024
Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022–2023, 2023–2024, and 2024–2025 seasons
Reports of Encephalopathy Among Children with Influenza-Associated Mortality - United States, 2010-11 Through 2024-25 Influenza Seasons
Notes from the Field: Expanding Birthing Hospital Enrollment in the Vaccines for Children Program to Increase Infant Immunization Against Respiratory Syncytial Virus - United States, October 2023-March 2025
Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025
Notes from the Field: Severe Medetomidine Withdrawal Syndrome in Patients Using Illegally Manufactured Opioids - Pittsburgh, Pennsylvania, October 2024-March 2025
Emergency Department Survey of Vaccination Knowledge, Vaccination Coverage, and Willingness to Receive Vaccines in an Emergency Department Among Underserved Populations - Eight U.S. Cities, April-December, 2024
Vaccination Coverage Among Adolescents Aged 13-17 Years - National Immunization Survey-Teen, United States, 2024
Nirsevimab Effectiveness Against Intensive Care Unit Admission for Respiratory Syncytial Virus in Infants - 24 States, December 2024-April 2025
Notes from the Field: Parvovirus B19 Activity - United States, January 2024-May 2025
